Severe Self-Mutilation of the Eye as a First Sign of Psychosis – a case Report

Česká verzia

Authors: M. Molnárová; M. Izák; P. Demský; R. Vida; V. Lešková
Authors place of work: II. očná klinika SZU FNsP F. D. Roosevelta Banská Bystrica, prednosta prof. MUDr. Milan Izák, CSc., FEBO
Published in the journal: Čes. a slov. Oftal., 65, 2009, No. 6, p. 203-206
Category: Overview Report

Summary

In a group of 93 patients (32 males, 61 females) with mean age of 74 (from 58 to 87 years) with mean follow-up of 15.1 months we retrospectively studied the effectivity and safety of intravitreal aplication of pegaptanib sodium = Macugen in a case of age-related macular degeneration (AMD). All patients met inclusion criteria. The treatment was performed on outpatient basis, following strict performance criteria. Improvement of visual acuity in the follow-up we observed in 48 patients (51.6%) stabilization of visual acuity in 19 patients (20.4%). In 26 (28%) patients the visual acuity deteriorated. The reason of deterioration in 3 patients was subretinal hemorrhage, in 1 case detachment of the retina and 22 patients did not respond to the treatment and in the follow up the local finding slowly progressed. We observed serious preoperative complications in 4 patients. They had high intraocular pressure with stop of perfusion in arteria centralis retinae after application, in 3 patients we did immediately decompressive paracentesis and in 1 case we applied local digital massage and i.v. application of antigalaucoma drug. All 4 cases fully recovered. Postoperatively we observed in 2 cases progression of cataract, for wich we did surgery. Comparing our results to VISION study, we observed a greater benefit of intravitreal application of Macugen in the case of wet form of age-related macular degeneration.

Key words:
CNV VPDM, intravitreal therapy, antiVEGF – Macugen

Zdroje

1. Duan, Y., MO,J., Klein, RE., et al.: Age-related Macular Degeneration is associated with incident myocardial infarction in elderly Americans. Ophthalmol., 114, 2007; 732–737.

2. Gradoudas, E.S., Adami, A.P., Cunningham, E.T. et al.: VEGF Inhibition Study in Ocular Neovascular Clinical Trial Group. Pegaptanib for neovascular age-related mcular degeneration. N. Engl. J. Med., 351, 2004; 2805–2816.

3. Hyman, L., Schachat, A., Leske, M.C.: Hypertension, cardiovascular disease and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch. Ophthalmol., 118, 2000; 351–358.

4. Ishida, S., Usui, T., Yamashiro, K. et al.: VEGF 164-mediated inflammation is required for pathological, but not physiological, ischemia- reduced retinal neovasculariosation. J. Exp. Med., 198, 2003; 483–489.

5. Klein, R., Klein, B.E.K., Jenson, S.C. et al.: The 5-year incidence of age-related maculopathy in Beaver Dam Eye Study. Investigative Ophthalmology and Visual Science, 1996; 37, 412.

6. Kolař, P. a kol.: Věkem podmíněná makulární degenerace. Grada Publishing, 2008; 148.

7. Leibowitz, H.M., Krueger, D.E., Maunder, L.R., et al.: The Framingham Eye Study Monograph. Surv. Ophthalmol., 24,1980; 335–610.

8. White, R.R., Sullenger, B.A., Rusconi, C.P.: Developing aptamers into therapeutics. J. Clin. Invest., 106, 2000; 929–934.